Home Cart Sign in  
Chemical Structure| 1887014-12-1 Chemical Structure| 1887014-12-1

Structure of Olutasidenib
CAS No.: 1887014-12-1

Chemical Structure| 1887014-12-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Olutasidenib is an orally effective IDH1 inhibitor that crosses the blood-brain barrier and exhibits significant inhibitory effects on IDH1-R132H and IDH1-R132C mutants.

Synonyms: FT-2102

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Olutasidenib

CAS No. :1887014-12-1
Formula : C18H15ClN4O2
M.W : 354.79
SMILES Code : N#CC1=CC=C(N[C@H](C2=CC3=C(NC2=O)C=CC(Cl)=C3)C)C(N1C)=O
Synonyms :
FT-2102
MDL No. :MFCD31746915

Safety of Olutasidenib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06566742 Myelodysplastic Syndromes|Chro... More >>nic Myelomonocytic Leukemia|Clonal Cytopenia of Undetermined Significance Less << PHASE2 NOT_YET_RECRUITING 2029-08-31 MD Anderson Cancer Center, Hou... More >>ston, Texas, 77030, United States Less <<
NCT06668584 Myeloid Malignancies PHASE2 RECRUITING 2029-12-31 The University of Texas M. D. ... More >>Anderson Cancer Center, Houston, Texas, 77030, United States Less <<
NCT06597734 Chronic Myelomonocytic Leukemi... More >>a|Advanced Myeloproliferative Neoplasms|IDH1-mutated Higher-Risk Myelodysplastic Syndromes Less << PHASE2 RECRUITING 2029-08-31 MD Anderson Cancer Center, Hou... More >>ston, Texas, 77030, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.82mL

0.56mL

0.28mL

14.09mL

2.82mL

1.41mL

28.19mL

5.64mL

2.82mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories